Pharmacy World and Science

, Volume 27, Issue 2, pp 129–134 | Cite as

Volume and market share of anti-epileptic drugs in the Netherlands: impact of new drugs

  • Pieter KnoesterEmail author
  • Charles Deckers
  • Ronald van der Vaart
  • Bert Leufkens
  • Yechiel Hekster
Research Article


Objective: In the past decade, several new anti-epileptic drugs (AEDs) were introduced in the Netherlands. These new drugs, one of which is lamotrigine, are 6 to 10 times more expensive than conventional anti-convulsants. In 1997, the high cost of lamotrigine, together with a lack of clinical data supporting its superiority over conventional drugs, prompted the Dutch Health Insurance Board to release a guideline in which the use of lamotrigine was restricted to difficult-to-treat patients. Other new drugs that were marketed after 1997 also became subject to this guideline. The utilisation of new AEDs and the cost consequences are the subject of this paper.

Methods: Data from extramurally prescribed AEDs was obtained from the Dutch Drug Information Project, which is a database containing prescriptions for about 5.5 million inhabitants of the Netherlands. This data was used to study the impact of new AEDs on volume and market share of AEDs in the period from 1995 to 2001 in the Netherlands.

Results: Between 1995 and 2001, the total volume of AEDs increased by 130%, 60% of which consisted of new AEDs. Gabapentin, lamotrigine and oxcarbazepine were the most frequently prescribed new compounds. The volume share of new AEDs increased from 5% in 1995 to 18% in 2001. The market share amounted to 21.5 million euros in 1995 and rose to 47 million euros in 2001; 80% of this increase was due to the introduction of new AEDs.

Discussion: Although in 2001 the volume share of new AEDs was still modest, their introduction has led to a strong increase in the cost. New data is emerging on the effectiveness and cost-benefit sum of the new AEDs; this may change the place in therapy of these drugs. Because of their strong potential to force up cost, the positioning of new AEDs requires further attention.


Antiepileptic drugs ATC-DDD system Drug utilisation Pharmacoepidemiology Pharmacoeconomics The Netherlands 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Mattson, RH, Cramer, JA, Collins, JF. 1992A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 GroupN Engl J Med32776571PubMedGoogle Scholar
  2. Mattson, RH, Cramer, JA, Collins, JF.,  et al. 1985Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizuresN Engl J Med:31314551Google Scholar
  3. Heaney, D. 1999The pharmacoeconomics of the new antiepileptic drugsEpilepsia.402531PubMedGoogle Scholar
  4. Kotsopoulos, IA, Evers, SM, Ament, AJ.,  et al. 2001Estimating the costs of epilepsy: an international comparison of epilepsy cost studiesEpilepsia.4263440CrossRefPubMedGoogle Scholar
  5. Trenite, DG, Rentmeester, TW, Scholtes, FB.,  et al. 2001Peri-marketing surveillance of lamotrigine in the Netherlands: doctors’ and patients’ viewpointsPharm World Sci:2315CrossRefGoogle Scholar
  6. World Health Organization, Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: WHO, 1998. Ref Type: ReportGoogle Scholar
  7. Mantel-Teeuwisse, AK, Klungel, OH, Verschuren, WM.,  et al. 2001Comparison of different methods to estimate prevalence of drug use by using pharmacy recordsJ Clin Epidemiol.5411816CrossRefPubMedGoogle Scholar
  8. Beghi, E, Monticelli, ML, Monza, G.,  et al. 1991Antiepileptic drugs as ’tracers’ of disease. A calculation of the prevalence of epilepsy through an analysis of drug consumption. The Group for the Study of Epilepsy in General Practice.Neuroepidemiology103341PubMedGoogle Scholar
  9. Banfi, R, Borselli, G, Marinai, C.,  et al. 1995Epidemiological study of epilepsy by monitoring prescriptions of antiepileptic drugsPharm World Sci.1713840PubMedGoogle Scholar
  10. Lammers, MW, Hekster, YA, Keyser, A.,  et al. 1996Use of anti-epileptic drugs in a community-dwelling Dutch populationNeurology.46627PubMedGoogle Scholar
  11. Shackleton, DP, Westendorp, RG, Kasteleijn-Nolst Trenite, DG.,  et al. 1997Dispensing epilepsy medication: a method of determining the frequency of symptomatic individuals with seizuresJ Clin Epidemiol.5010618CrossRefPubMedGoogle Scholar
  12. Roberts, SJ, Feely, M, Bateman, DN. 1998Prescribing of anti-epileptic drugs in the northern and Yorkshire region: 1992-1995Seizure712732CrossRefPubMedGoogle Scholar
  13. Rochat, P, Hallas, J, Gaist, D.,  et al. 2001Antiepileptic drug utilization: a Danish prescription database analysisActa Neurol Scand.104611CrossRefPubMedGoogle Scholar
  14. Banfi, R, Borselli, G, Marinai, C.,  et al. 1995Epidemiological study of epilepsy by monitoring prescriptions of antiepileptic drugsPharm World Sci.1713840PubMedGoogle Scholar
  15. Botts, SR, Raskind, J. 1999Gabapentin and lamotrigine in bipolar disorderAm J Health Syst Pharm.56193944PubMedGoogle Scholar
  16. Gorson, KC, Schott, C, Herman, R.,  et al. 1999Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trialJ Neurol Neurosurg Psychiatry.662512PubMedGoogle Scholar
  17. Pande, AC, Crockatt, JG, Janney, CA.,  et al. 2000Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy Gabapentin Bipolar Disorder Study GroupBipolar Disord.224955CrossRefPubMedGoogle Scholar
  18. Simpson, DM, Olney, R, McArthur, JC.,  et al. 2000A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathyNeurology.5421159PubMedGoogle Scholar
  19. Ichim, L, Berk, M, Brook, S. 2000Lamotrigine compared with lithium in mania: a double-blind randomized controlled trialAnn Clin Psychiatry.12510CrossRefPubMedGoogle Scholar
  20. Meijer, WE, Heerdink, ER, Pepplinkhuizen, LP.,  et al. 2001Prescribing patterns in patients using new antidepressantsBr J Clin Pharmacol.511813CrossRefPubMedGoogle Scholar
  21. Petri, H, Urquhart, J. 1991Channelling bias in the interpretation of drug effectsStat Med.1057781PubMedGoogle Scholar
  22. Eke, T, Talbot, JF, Lawden, MC. 1997Severe persistent visual field constriction associated with vigabatrinBMJ.3141801PubMedGoogle Scholar
  23. Pellock, JM. 1999Felbamate in epilepsy therapy: evaluating the risksDrug Saf.2122539PubMedGoogle Scholar
  24. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and car- 6Google Scholar
  25. Brodie, MJ, Mumford, JP. 1999Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study groupEpilepsy Res.34199205CrossRefPubMedGoogle Scholar
  26. Reunanen, M, Dam, M, Yuen, AW. 1996A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsyEpilepsy Res.2314955CrossRefPubMedGoogle Scholar
  27. Steiner, TJ, Dellaportas, CI, Findley, LJ.,  et al. 1999Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoinEpilepsia.406017PubMedGoogle Scholar
  28. Christe, W, Kramer, G, Vigonius, U.,  et al. 1997A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsyEpilepsy Res.2645160CrossRefPubMedGoogle Scholar
  29. Dam, M, Ekberg, R, Loyning, Y.,  et al. 1989A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsyEpilepsy Res.3706CrossRefPubMedGoogle Scholar
  30. Gillham, R, Kane, K, Bryant-Comstock, L.,  et al. 2000A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measureSeizure.93759CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Pieter Knoester
    • 1
    Email author
  • Charles Deckers
    • 1
    • 2
  • Ronald van der Vaart
    • 3
  • Bert Leufkens
    • 4
  • Yechiel Hekster
    • 1
  1. 1.Department of Clinical PharmacyUniversity Medical Centre NijmegenNijmegenThe Netherlands
  2. 2.Dutch Epilepsy Clinics FoundationLocation ZwolleThe Netherlands
  3. 3.Dutch Drug Information ProjectHealth Care Insurance BoardAmstelveenThe Netherlands
  4. 4.Department of Pharmacoepidemiology and PharmacotherapyUtrecht Institute for Pharmaceutical Sciences (UIPS)UtrechtThe Netherlands

Personalised recommendations